BerGenBio to merge with Oncoinvent in a $16.2m deal.

BerGenBio, a clinical-stage biopharmaceutical company, agreed to merge with Oncoinvent, a clinical-stage radiopharmaceutical company, in a $16.2m deal. “We are very excited for the time ahead and to continue the execution of our focused strategy to develop Radspherin® in ovarian cancer. We are on track with our randomised phase 2 trial. Going forward with a strengthened balance sheet, we believe the company will be a transformative force in the radiopharmaceutical therapy field, improving the lives of patients with cancer in the peritoneal cavity,” Øystein Soug, Oncoinvent CEO.